Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.36 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7239139 | 1.00 | MAPT (0.46) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL7242738 | 0.84 | CYP1A2 (0.55) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL7242741 | 0.84 | CYP1A2 (0.55) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL6789277 | 0.80 | CYP1A2 (0.44) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL11549758 | 0.76 | LMNA (0.64) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL11549769 | 0.76 | LMNA (0.64) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL11546810 | 0.75 | MAPT (0.55) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL11546817 | 0.75 | MAPT (0.55) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL15026459 | 0.74 | MAPT (0.54) | MAPTKMT2ALMNAKDM4EHSP90AA1 | |
| SCHEMBL10376090 | 0.73 | LMNA (0.51) | MAPTKMT2ALMNAKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630494-B2 | Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | US | disclosed |
| US-6239155-B1 | TREATMENT OF CENTRAL DEGENERATIVE DISORDERS, AS DEMENTIAS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR AMYOTROPHIC LATERAL SCLEROSIS, MEMORY IMPAIRMENT, DEPRESSIONS, MIGRAINE, OF NEUROPATHIES, METABOLIC DISORDERS SUCH AS DIABETES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-29 | — | — | US | disclosed |
| US-6066655-A | FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, IN PARTICULAR AS CEREBRAL THERAPEUTICS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-23 | — | — | US | disclosed |
| US-5731333-A | LEARNING AND MEMORY ENHANCEMENT, ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | GRIK4, PKM, PDK4 | MAPT 565/4885KMT2A 346/4885LMNA 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.